AbbVie stock: At 1.84 percent below its 52-week high, AbbVie stock trades at EUR 255.05

Published on 10/19/2026 at 16:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie stock costs EUR 255.05 on October 19, 2026, plus 0.77 percent versus the Xetra close. UBS set a USD 275 target on October 9, 2026.

Price near yearly high

AbbVie stock stood 1.84 percent below its 52-week high on October 19, 2026.
UBS raised its AbbVie target to USD 275 on October 9, 2026.
AbbVie stock costs EUR 255.05 at Lang & Schwarz on October 19, 2026 at 4:10 p.m. CEST, 0.77 percent above the Xetra close of October 16, 2026.
AbbVie will report third-quarter results on October 30, 2026.

Fotorealistisches Pharma-Forschungslabor mit Petrischalen und Wissenschaftlern in Schutzkleidung — AbbVie Inc. US00287Y1091 fotorealistisches Pharma Forschungslabor mit Petrischalen Wissenschaftlern Immunologie Onkologie Biopharma, Illustration mit AI erstellt.

On October 19, 2026, AbbVie stock traded near its yearly high: the USD 286.04 NYSE price stood 1.84 percent below the USD 291.40 52-week high. At Lang & Schwarz, AbbVie stock was trading at EUR 255.05 at 4:10 p.m. CEST, 0.77 percent above the Xetra close of October 16, 2026, at EUR 253.10.

Analyst target remains below market price

Markets Insider reported on October 9, 2026 that UBS analyst Michael Yee raised the target for AbbVie from USD 260.00 to USD 275.00 and kept a Neutral rating. The target is 3.86 percent below the USD 286.04 NYSE price, making the distance to the target a counterweight to the stock's position near its yearly high.

Results date sets the next checkpoint

AbbVie said on October 1, 2026 that it will announce third-quarter 2026 results before the market opens on October 30, 2026. The scheduled report gives the market a defined date for testing the valuation and the analyst target.

EUR 255.05 within the yearly range

The euro quote was supported by a narrow daily move against the Xetra close. On the NYSE, AbbVie traded at USD 286.04 at 10:23 a.m. EDT on October 19, 2026, up 0.22 percent from USD 285.42. Trading volume was 776,822 shares against an average of 4,843,490 shares. The primary-market 52-week range ran from USD 190.75 to USD 291.40.

Comparison with peers

AbbVie Inc.: plus 0.77 percent, P/E 80.51, market capitalization USD 505.5 billion
Amgen (NASDAQ, USD): plus 0.06 percent, P/E 26.89, market capitalization USD 234.0 billion
Gilead Sciences (NASDAQ, USD): plus 0.30 percent, P/E minus 58.72, market capitalization USD 194.3 billion

Price and next date

The valuation picture combines a high P/E of 80.51 with a market capitalization of USD 505.5 billion and a scheduled results date. For investors, the October 30 report is the next dated test of whether operating performance can support the current market level and the USD 275 UBS target.

AbbVie stock was trading at EUR 255.05 at Lang & Schwarz on October 19, 2026 at 4:10 p.m. CEST, 0.77 percent above the Xetra close of October 16, 2026 at EUR 253.10. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.